Patent Application
20220152037
Disclosed herein are methods of treating fibromyalgia comprising administering to a subject in need thereof a therapeutically effective amount of a compound that is a GABAA receptor modulator. Also disclosed herein are compositions for use in treating fibromyalgia comprising a therapeutically effective amount of a compound that is a GABAA receptor modulator. In some embodiments, the compound is a positive GABAA receptor modulator. In some embodiments, the compound is a positive allosteric GABAA receptor modulator. In some embodiments, the compound is an α1, α2, α3, or α5 GABAA receptor modulator. In some embodiments, the compound is a positive allosteric α2 or α3 GABAA receptor modulator. In some embodiments, the compound is of the general formula (1a), general formula (1b), general formula (1c), or a pharmaceutically acceptable salt or solvate thereof,
In some embodiments, the compound is of the general formula (2a), (3a), (4a), (5a), (5b), (1c), (7a), or a pharmaceutically acceptable salt or solvate thereof,
In some embodiments, m of R1 is 1, and wherein R1 is: an unsubstituted phenyl, a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, —CN as substituents, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, a substituted biphenyl comprising at least one —CN as a substituent, or —(C═O)—R3, wherein R3 is pyridine. In some embodiments, the compound is of the general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI), (7a′), or a pharmaceutically acceptable salt or solvate thereof,
In some embodiments, R1 is: an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, or a substituted biphenyl comprising at least one F as a substituent. In some embodiments, R1 is a substituted biphenyl comprising —CN and F. In some embodiments, R7 is an unsubstituted C1-C6 alcohol. Disclosed herein are methods of treating fibromyalgia comprising administering to a subject in need thereof a therapeutically effective amount of a compound that is a GABAA receptor modulator, wherein the compound is
or a pharmaceutically acceptable salt or solvent thereof. In some embodiments, the subject is a human. In some embodiments, the subject is a dog.
Disclosed herein are methods of treating pain in a subject comprising administering to the subject an amount of a pharmaceutical composition comprising a compound selected from the group consisting of:
and pharmaceutically acceptable salts or solvents thereof, wherein the amount is effective to treat the pain when the compound, or a pharmaceutically acceptable salt or solvent thereof, is administered at a dose of from about 0.001 mg/kg per day to about 3.0 mg/kg per day of a body weight of the subject. Also disclosed herein are compositions for use in treating pain comprising a compound selected from the group consisting of:
and pharmaceutically acceptable salts or solvents thereof, wherein the compound or pharmaceutically acceptable salt or solvent thereof is present in a unit dose sufficient to deliver from about 0.001 mg/kg to about 3.0 mg/kg of the compound with respect to a body weight of a subject. In some embodiments, the compound is:
or a pharmaceutically acceptable salt or solvent thereof. In some embodiments, the compound is
or a pharmaceutically acceptable salt or solvent thereof. In some embodiments, the method comprises administering an amount of a compound, or a pharmaceutically acceptable salt or solvent thereof at a dose of at most about 0.3 mg/kg per day of a body weight of the subject. In some embodiments, the method comprises administering an amount of a compound, or a pharmaceutically acceptable salt or solvent thereof at a dose of at most about 0.03 mg/kg per day of a body weight of the subject. In some embodiments, the composition for use comprises a unit dose sufficient to deliver at most about 0.3 mg/kg per day of a body weight of a subject. In some embodiments, the composition for use comprises a unit dose sufficient to deliver at most about 0.03 mg/kg per day of a body weight of the subject. In some embodiments, the pain is related to central nervous system sensitization. In some embodiments, the pain is chronic. In some embodiments, the subject is a human. In some embodiments, the subject is a dog. In some embodiments, the pharmaceutical composition or composition for use further comprises a pharmaceutically acceptable excipient, diluent, or carrier. In some embodiments, the pharmaceutical composition or composition for use comprises a carrier, and wherein the carrier is methyl cellulose. In some embodiments, the administering comprises an oral administration. In some embodiments, the administering is performed at least once a day.
Disclosed herein are methods of treating fibromyalgia in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a compound of:
or a pharmaceutically acceptable salt or solvent thereof, and a pharmaceutically acceptable excipient, diluent, or carrier. Also disclosed herein are compositions for use in treating fibromyalgia comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvent thereof, and a pharmaceutically acceptable excipient, diluent, or carrier. In some embodiments, the pharmaceutical composition or composition for use comprises
or a pharmaceutically acceptable salt or solvent thereof. In some embodiments, the pharmaceutical composition or composition for use comprises
or a pharmaceutically acceptable salt or solvent thereof. In some embodiments, the method comprises administering the compound or a pharmaceutically acceptable salt or solvent thereof at a dose of from about 0.001 mg/kg per day to about 3.0 mg/kg per day of a body weight of the subject. In some embodiments, the method comprises administering the compound or a pharmaceutically acceptable salt or solvent thereof is administered at a dose of at most about 0.3 mg/kg per day of a body weight of the subject. In some embodiments, the compound or a pharmaceutically acceptable salt or solvent thereof is administered at a dose of at most about 0.03 mg/kg per day of a body weight of the subject. In some embodiments, the composition for use comprises a unit dose sufficient to deliver at most about 0.3 mg/kg per day of a body weight of a subject. In some embodiments, the composition for use comprises a unit dose sufficient to deliver at most about 0.03 mg/kg per day of a body weight of the subject. In some embodiments, the subject has a fibromyalgia-associated allodynia.
Disclosed herein are methods of treating fibromyalgia comprising administering to the subject a compound that is a GABAA receptor modulator. Also disclosed herein are compositions for use in treating fibromyalgia comprising a compound that is a GABAA receptor modulator. In some embodiments, a compound is of the general formula (1a), general formula (1b) or general formula (1c),
wherein X1, X2, X3, X4 and X5 are independently —C, —N, —S or —O wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently —C or —N, m of R1m is 1, wherein R1 is an unsubstituted phenyl, a phenyl substituted with C1-C4-alkyl, F, Cl, Br, I, —CN, a substituted or unsubstituted biphenyl or —(C═O)—R3, wherein R3 is a substituted or unsubstituted aryl or 5- to 6-membered heteroaryl, n of R2n is 1 or 2, wherein each R2 is independently a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted 6-membered heteroaryl, a halogen, or —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5- or 6-membered heteroaryl, Z1, Z3, Z4, and Z5 are independently —C, —N, —S or —O, A1, and A2 and A3, are independently —C, —N, —(C═O)—O—R7, or
wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, s of R21s is 1, 2, 3 or 4, and R21 is independently hydrogen or C1-C6 alkyl, l of R5l is 1 or 2, wherein each R5 is independently a C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, p of R12 is 1 or 2, wherein each R12 is independently a substituted or unsubstituted C1-C4-alkyl, I, Br, Cl or F, and q of R13 is 1, 2, 3 or 4, wherein each R13 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen. In some embodiments, a compound is of the general formula (2), (3), (4), (5), (1c) or (7), In some embodiments, a compound is of the general formula (2a), (3a), (4a), (5a), (5b), (1c) or (7a)
In some embodiments, m of R1 is 1, and R1 is: an unsubstituted phenyl, a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, or —CN as substituents, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, a substituted biphenyl comprising at least one —CN as a substituent, or —(C═O)—R3, wherein R3 is pyridine. In some embodiments, a compound is of the general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI) or (7a′),
wherein R10 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, or p of R12 is 1 and R12 is I, Br, Cl or F. In some embodiments, a compound is of the general formula (2a″), (3a″), (4a″), (5a″), (5b″), (VIa″) or (7a″),
wherein R7 is: an unsubstituted C1-C6 alkyl, an unsubstituted C3-C8 cycloalkyl, an unsubstituted C1-C6 alcohol, R8 is: —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5-membered heteroaryl, or an unsubstituted C1-C6 alcohol, R9 is: an unsubstituted C6 heteroaryl, or a halogen, or R9 is an unsubstituted 6-membered heteroaryl in formula (4a″) or a halogen in formula (5b″), R10 is a C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl or heteroaryl, R14 is a substituted or unsubstituted aryl or heteroaryl, R12 is I, Cl, Br or F, or R5 is C2 alkinyl or I. In some embodiments, a compound is of the general formula (8):
wherein Z4 and Z5 are independently —C, —N, —S or —O, A1 and A2 are independently —C, —N or —(C═O)—O—R7, wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, l of R5l is 1 or 2, wherein R5 is C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, and s of R21s is 1, 2, 3 or 4, wherein each R21 is independently hydrogen or C1-C6 alkyl. In some embodiments, a compound is an α1, α2, α3, or α5 GABAA receptor modulator. In some embodiments, a compound is a positive, allosteric α2 or α3 GABAA receptor modulator. In some embodiments, a subject is a human. In some embodiments, a subject is a dog.
Also disclosed herein are methods of treating pain in a subject comprising administering to the subject a compound of the general formula (1a), general formula (1b) or general formula (1c),
wherein X1, X2, X3, X4 and X5 are independently —C, —N, —S or —O wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently —C or —N, m of R1m is 1, wherein R1 is an unsubstituted phenyl, a phenyl substituted with C1-C4-alkyl, F, Cl, Br, I, —CN, a substituted or unsubstituted biphenyl or —(C═O)—R3, wherein R3 is a substituted or unsubstituted aryl or 5- to 6-membered heteroaryl, n of R2n is 1 or 2, wherein each R2 is independently a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted 6-membered heteroaryl, a halogen, or —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5- or 6-membered heteroaryl, Z1, Z3, Z4, and Z5 are independently —C, —N, —S or —O, A1, and A2 and A3, are independently —C, —N, —(C═O)—O—R7, or
wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, s of R21s is 1, 2, 3 or 4, and R21 is independently hydrogen or C1-C6 alkyl, l of R5l is 1 or 2, wherein each R5 is independently a C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, p of R12 is 1 or 2, wherein each R12 is independently a substituted or unsubstituted C1-C4-alkyl, I, Br, Cl or F, and q of R13 is 1, 2, 3 or 4, wherein each R13 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen. Also disclosed herein are compositions for use treating pain comprising the compound. In some embodiments, a compound is of the general formula (2), (3), (4), (5), (1c) or (7),
In some embodiments, a compound is of the general formula (2a), (3a), (4a), (5a), (5b), (1c) or (7a)
In some embodiments, m of R1 is 1, and R1 is: an unsubstituted phenyl, a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, or —CN as substituents, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, a substituted biphenyl comprising at least one —F as a substituent, or —(C═O)—R3, wherein R3 is pyridine. In some embodiments, a compound is of the general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI) or (7a′),
wherein R10 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, or p of R12 is 1 and R12 is I, Br, Cl or F. In some embodiments, a compound is of the general formula (2a″), (3a″), (4a″), (5a″), (5b″), (VIa″) or (7a″),
wherein R7 is: an unsubstituted C1-C6 alkyl, an unsubstituted C3-C8 cycloalkyl, an unsubstituted C1-C6 alcohol, R8 is: —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5-membered heteroaryl, or an unsubstituted C1-C6 alcohol, R9 is: an unsubstituted C6 heteroaryl, or a halogen, or R9 is an unsubstituted 6-membered heteroaryl in formula (4a″) or a halogen in formula (5b″), R10 is a C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl or heteroaryl, R14 is a substituted or unsubstituted aryl or heteroaryl, R12 is I, Cl, Br or F, or R5 is C2 alkinyl or I. In some embodiments, a compound is of the general formula (8):
wherein Z4 and Z5 are independently —C, —N, —S or —O, A1 and A2 are independently —C, —N or —(C═O)—O—R7, wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, l of R5l is 1 or 2, wherein R5 is C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, and s of R21s is 1, 2, 3 or 4, wherein each R21 is independently hydrogen or C1-C6 alkyl. In some embodiments, a compound is an α1, α2, α3, or α5 GABAA receptor modulator. In some embodiments, a compound is a positive, allosteric α2 or α3 GABAA receptor modulator. In some embodiments, a subject is a human. In some embodiments, a subject is a dog.
Also disclosed herein are methods of treating allodynia in a subject comprising administering to the subject a compound of the general formula (1a), general formula (1b) or general formula (1c),
wherein X1, X2, X3, X4 and X5 are independently —C, —N, —S or —O wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently —C or —N, m of R1m is 1, wherein R1 is an unsubstituted phenyl, a phenyl substituted with C1-C4-alkyl, F, Cl, Br, I, —CN, a substituted or unsubstituted biphenyl or —(C═O)—R3, wherein R3 is a substituted or unsubstituted aryl or 5- to 6-membered heteroaryl, n of R2n is 1 or 2, wherein each R2 is independently a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted 6-membered heteroaryl, a halogen, or —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5- or 6-membered heteroaryl, Z1, Z3, Z4, and Z5 are independently —C, —N, —S or —O, A1, and A2 and A3, are independently —C, —N, —(C═O)—O—R7, or
wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, s of R21s is 1, 2, 3 or 4, and R21 is independently hydrogen or C1-C6 alkyl, l of R5l is 1 or 2, wherein each R5 is independently a C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, p of R12 is 1 or 2, wherein each R12 is independently a substituted or unsubstituted C1-C4-alkyl, I, Br, Cl or F, and q of R13 is 1, 2, 3 or 4, wherein each R13 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen. Also disclosed herein are compositions for use in treating allodynia comprising the compound. In some embodiments, a compound is of the general formula (2), (3), (4), (5), (1c) or (7),
In some embodiments, a compound is of the general formula (2a), (3a), (4a), (5a), (5b), (1c) or (7a)
In some embodiments, m of R′ is 1, and R′ is: an unsubstituted phenyl, a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, or —CN as substituents, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, a substituted biphenyl comprising at least one —F as a substituent, or —(C═O)—R3, wherein R3 is pyridine. In some embodiments, a compound is of the general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI) or (7a′),
wherein R10 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, or p of R12 is 1 and R12 is I, Br, Cl or F. In some embodiments, a compound is of the general formula (2a″), (3a″), (4a″), (5a″), (5b″), (VIa″) or (7a″),
wherein R7 is: an unsubstituted C1-C6 alkyl, an unsubstituted C3-C8 cycloalkyl, an unsubstituted C1-C6 alcohol, R8 is: —O—CH2—R4, wherein R4 is a substituted or unsubstituted 5-membered heteroaryl, or an unsubstituted C1-C6 alcohol, R9 is: an unsubstituted C6 heteroaryl, or a halogen, or R9 is an unsubstituted 6-membered heteroaryl in formula (4a″) or a halogen in formula (5b″), R10 is a C1-C3 alkyl or hydrogen, R11 is a substituted or unsubstituted aryl or heteroaryl, R14 is a substituted or unsubstituted aryl or heteroaryl, R12 is I, Cl, Br or F, or R5 is C2 alkinyl or I. In some embodiments, a compound is of the general formula (8):
wherein Z4 and Z5 are independently —C, —N, —S or —O, A1 and A2 are independently —C, —N or —(C═O)—O—R7, wherein R7 is alkyl, B1, B2, B3, and B4 are independently —C, —N, or —O, l of R5l is 1 or 2, wherein R5 is C1-C4 alkinyl or a halogen, k of R6k is 1, 2, 3 or 4, wherein each R6 is independently a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen, and s of R21s is 1, 2, 3 or 4, wherein each R21 is independently hydrogen or C1-C6 alkyl. In some embodiments, a compound is an α1, α2, α3, or α5 GABAA receptor modulator. In some embodiments, a compound is a positive, allosteric α2 or α3 GABAA receptor modulator. In some embodiments, a subject is a human. In some embodiments, a subject is a dog.
Also disclosed herein are methods of treating pain in a subject comprising administering to the subject an amount of a pharmaceutical composition comprising a compound selected from the group consisting of:
Also disclosed herein are compositions for use in treating pain comprising the compound. In some embodiments, a compound is:
In some embodiments, an amount is effective to treat the pain when administered at a dose of from about 0.3 mg/kg per day to about 3.0 mg/kg per day of a body weight of a subject. In some embodiments, pain is related to central nervous system sensitization. In some embodiments, pain is chronic. In some embodiments, a subject is a human. In some embodiments, a subject is a dog. In some embodiments, a pharmaceutical composition or composition for use further comprises a pharmaceutically acceptable excipient, diluent, or carrier. In some embodiments, a pharmaceutical composition or composition for use comprises a carrier, wherein the carrier is methyl cellulose. In some embodiments, an administering comprises an oral administration. In some embodiments, an administering is performed at least once a day.
Also disclosed herein are methods of treating fibromyalgia, allodynia, hypersensitivity, or pain associated with central nervous system sensitization in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a compound of:
Also disclosed herein are compositions for use in treating fibromyalgia, allodynia, hypersensitivity, or pain comprising the compound.
Further described herein are GABAA receptor modulators or pharmaceutical compositions comprising the modulators for use in the treatment of fibromyalgia, allodynia, hypersensitivity, or pain associated with central nervous system sensitization in a subject in need thereof. In some embodiments, described herein are compounds, pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions comprising the compounds, salts, or solvates, for use in the treatment of fibromyalgia, allodynia, hypersensitivity, or pain associated with central nervous system sensitization in a subject in need thereof. In some embodiments, described herein is Compound 1, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of fibromyalgia.
The novel features of exemplary embodiments are set forth with particularity in the appended claims. A better understanding of the features and advantages will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of exemplary embodiments are utilized, and the accompanying drawings of which:
The term “GABA receptor” refers to receptors of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). GABAA receptors (ionotropic receptors) are ligand-gated ion channels and GABAB receptors, also known as metabotropic receptors, are G protein-coupled receptors. GABAA receptors are the most common and most important inhibitory receptors within the central nervous system. GABAA receptors comprise five subunits that are grouped in eight classes: α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3. The majority of GABAA receptors comprise two α, two β and one γ subunit. Compounds such as benzodiazepines can bind to sites distinct from the endogenous ligand GABAA For example, a benzodiazepine can bind to a binding site situated between the α and γ subunits. A compound described herein can be an allosteric modulator of a GABAA receptor. The different types of a subunits confer different properties to the GABAA receptor. Whereas the α1 subunit is among other functions responsible for the sedative effect of benzodiazepines, the α2 subunit is connected, among other things, to the anxiolytic function of the receptors and the α3 subunit confers, among other things, the muscle relaxing properties of the GABAA receptor.
As used herein, the term “GABAA receptor modulator” refers to a substance that modulates the activities of GABAA receptors, provided that a GABAA receptor modulator is not gamma-aminobutyric acid. A positive GABAA receptor modulator increases the activity of GABAA receptor protein. A negative GABAA receptor modulator decreases the activity of GABAA receptor protein.
The term “allosteric modulator” refers to a substance that indirectly modulates the effects of an agonist at a receptor. A positive allosteric modulator induces an amplification of the agonist's effect, without having an effect by itself in the absence of the agonist. An allosteric modulator can bind to a site distinct from the agonist's binding site (allosteric). A negative allosteric modulator reduces the agonist's effect at a receptor, without having an effect by itself in the absence of the agonist.
The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, or within 2-fold, of a value.
The term “subject”, “patient” or “individual” as used herein encompasses a mammal and a non-mammal. A mammal can be any member of the Mammalian class, including but not limited to a human, a non-human primates such as a chimpanzee, an ape or other monkey species; a farm animal such as cattle, a horse, a sheep, a goat, a swine; a domestic animal such as a rabbit, a dog (or a canine), and a cat (or a feline); a laboratory animal including a rodent, such as a rat, a mouse and a guinea pig, and the like. A non-mammal can include a bird, a fish and the like. In some embodiments, a subject can be a mammal. In some embodiments, a subject can be a human. In some instances, a human can be an adult. In some instances, a human can be a child. In some instances, a human can be age 0-17 years old. In some instances, a human can be age 18-130 years old. In some instances, a subject can be a male. In some instances, a subject can be a female. In some instances, a subject can be diagnosed with, or can be suspected of having, a condition or disease. In some instances a disease or condition can be pain or a condition associated with pain. A subject can be a patient. A subject can be an individual. In some instances, a subject, patient or individual can be used interchangeably.
The terms “treat,” “treating”, “treatment,” “ameliorate” or “ameliorating” and other grammatical equivalents as used herein, include alleviating, or abating a disease or condition symptoms, inhibiting a disease or condition, e.g., arresting the development of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, relieving a condition caused by the disease or condition, or stopping symptoms of a disease or condition.
A “C1-C6 alkyl” refers to a saturated linear or branched hydrocarbon having 1, 2, 3, 4, 5 or 6 carbon atoms, wherein one carbon-carbon bond may be unsaturated and one CH2 moiety may be exchanged for oxygen (ether bridge). Non-limiting examples for a C1-C4 alkyl are methyl, ethyl, propyl, prop-2-enyl, n-butyl, 2-methylpropyl, tert-butyl, but-3-enyl, prop-2-inyl and but-3-inyl.
The term “aryl” refers to a cyclic aromatic C5-C10 hydrocarbon. Examples of aryl can include, without being restricted to, phenyl, naphthyl and heteroaryl. A heteroaryl can refer to an aryl that comprises one or several nitrogen, oxygen and/or sulfur atoms. Examples for heteroaryl can include, without being restricted to, pyrrole, thiophene, furan, imidazole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, thiazin, quinoline, benzofuran and indole. An aryl or a heteroaryl can be substituted by one or more alkyl groups. The term “aryl” can refer to a hydrocarbon with alternating double and single bonds between the carbon atoms forming a ring structure (in the following an “aromatic hydrocarbon”).
The term “heteroaryl” refers to aryl compounds in which at least one ring carbon atom is replaced with an oxygen, a nitrogen or a sulfur atom. The aromatic hydrocarbon may be neutral or charged. Examples of aryl or hetero aryl groups can include benzene, pyridine, pyrrole or cyclopenta-1,3-diene-anion. Aryl or hetero aryl groups as used herein may optionally include further substituent groups.
The term “substituted,” “substituent” or the like, unless otherwise indicated, refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, oxo, thioxy, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and an aliphatic group. It is understood that the substituent may be further substituted.
The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents, independently chosen from the group of possible substituents. When indicating the number of substituents, the term “one or more” means from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents.
As used herein, C1-Cx (or C1-x) includes C1-C2, C1-C3 . . . C1-Cx. By way of example only, a group designated as “C1-C4” indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms. Thus, by way of example only, “C1-C4 alkyl” indicates that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
Conditions
Disclosed herein are compounds for treatment of pain and associated conditions with heightened pain response. Such conditions can be chronic or acute. In some cases, a condition described herein can be triggered by external stimuli such as psychological stress, trauma, infections, or can be genetically inheritable. A condition can result from a sensitization of secondary pain neurons mediated by increased release of pro-inflammatory cytokines or nitric oxide by glial cells. In some cases, altered dopaminergic or noradrenergic signaling can produce a condition described herein. Some subjects suffering from a condition described herein may have increased levels of plasma cortisol, a decreased vasoconstriction response, decreased N-acetylaspartic acid, chronic inflammation due to increased levels of pro-inflammatory cytokines, heightened sensory sensations, disrupted sleep, insomnia, depression, numbness, concentration or memory problems, anxiety, morning stiffness, tingling in extremities, headaches, irritable bowel syndrome, painful urination, fatigue, and combinations thereof.
Compounds described herein (e.g. GABAA receptor modulators) can be used to at least partially ameliorate conditions associated with pain. In some cases, a condition that is associated with pain can include acute pain, addiction, advanced prostate cancer, AIDS-related pain, allodynia, ankylosing spondylitis, arachnoiditis, arthritis, arthrofibrosis, ataxic cerebral palsy, autoimmune atrophic gastritis, autoimmune diseases, avascular necrosis, back pain, Behcet's Disease (Syndrome), breakthrough pain, burning mouth syndrome, bursitis, CADASIL, cancer pain, carpal tunnel, Cauda Equina Syndrome, central pain syndrome, cerebral palsy, cerebrospinal fluid leaks, cervical stenosis, Charcot-Marie-Tooth Disease, chronic fatigue syndrome, chronic functional abdominal pain, chronic pain, chronic pancreatitis, coccyx, collapsed lung (pneumothorax), complementary and alternative medicine, complex regional pain syndrome, corneal neuropathic pain, Crohn's Disease, degenerative disc disease, depression, Dercum's Disease, dermatomyositis, diabetic peripheral neuropathy, dystonia, Ehlers-Danlos Syndrome, endometriosis, Eosinophilia-Myalgia Syndrome, erythromelalgia Failed Back Surgery Syndrome (FBSS), fibromyalgia, gout, headaches, herniated disc, hydrocephalus, intercostal neuraligia, interstitial cystitis, irritable bowel syndrome (IBS), Juvenile Dermatositis, injury, leg pain, Loin Pain-Haematuria Syndrome, lupus, Lyme Disease, medullary sponge kidney, meralgia paresthetica, mesothelioma, migraine, mitochondrial disorders, multiple sclerosis, musculoskeletal pain, myofascial pain, myositis, neck pain, neuropathic pain, occipital neuralgia, osteoarthritis, Paget's Disease, Parkinson's Disease, Parsonage Turner Syndrome, pelvic pain, peripheral neuropathy, phantom limb pain, pinched nerve, polycystic kidney disease, polymyalgia rhuematica, polymyositis, porphyria, post herniorraphy pain syndrome, post mastectomy pain syndrome, post stroke pain, post thorocotomy pain syndrome, postherpetic neuralgia, post-polio syndrome, post-traumatic stress disorder (PTSD), primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, radiculopathy, Raynaud's Disease, restless leg syndrome, rheumatoid arthritis, sacroiliac joint dysfunction, sarcoidosis, Scheuemann's Kyphosis Disease, sciatica, scoliosis, shingles (Herpes Zoster), sickle cell anemia, Sjogren's Syndrome, sleep apnea, spasmodic torticollis, sphincter of oddi dysfunction, spinal cerebellum ataxia, spinal cord injury, spinal stenosis, syringomyelia, tarlov cysts, Tethered Cord Syndrome, Thoracic Outlet Syndrome, TMJ, transverse myelitis, trigeminal neuralgia, trigger points, ulcerative colitis, vascular pain, visceral hypersensitivity, vulvodynia, and whiplasharthritis.
In some cases, a condition can be a hypersensitivity reaction. A hypersensitivity reaction can be a type I, type II, type III, or type IV hypersensitivity reaction. A type I hypersensitivity reaction can include anaphylaxis, a drug reaction, a food allergy, an insect venon allergy, and the like. A type II hypersensitivity reaction can include an acute hemolytic transfusion reaction, autoimmune hemolytic anemia, bullous pemphigoid drug-induced neutropenia, goodpasture syndrome, Graves disease, hemolytic disease of the fetus or newborn, immune thrombocytopenia, hyperacute transplant rejection, myasthenia gravis, pernicious anemia, pemphigus vulgaris, rheumatic fever, and the like. A type III hypersensitivity reaction can include arthus reaction, drug-induced hypersensitivity vasculitis, hypersensitivity pneumonitis, polyarteritis nodosa, poststreptococcal plomerulonephritis, lupus nephritis, serum sickness, systemic lupus erythematosus, and the like. A type IV hypersensitivity reaction can include acute or chronic transplant rejection, contact dermatitis, Stevens-Johnson Syndrome, Graft-versus-host disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, and the like.
In some cases, a condition associated with pain treatable with a compound described herein is fibromyalgia. A subject suffering from fibromyalgia that is treatable with a compound described herein may have additional associated conditions, such as depression, anxiety, migraine, allodynia, pelvic pain, headache, IBS, TMJ, tinnitus, gastrointestinal reflux disease, high blood pressure, or other conditions associated with pain as described herein.
In some cases, a condition associated with pain treatable with a compound described herein is allodynia. Allodynia can occur with or without other conditions as described herein such as fibromyalgia. In some embodiments, the condition is fibromyalgia-associated allodynia. In some embodiments, the fibromyalgia-associated allodynia is different from allodynia associated with other indications. In some embodiments, the fibromyalgia-associated allodynia is resistant to therapies that are effective in treating other types of allodynia.
Compounds
Disclosed herein are compounds for treatment of pain and associated conditions. In some cases, a compound for treatment of pain and associated conditions can be a GABAA receptor modulator. In certain embodiments, the compound is a positive allosteric α2 and/or α3 GABAA receptor modulator.
A GABAA receptor modulator that can be used in the treatment of pain and associated conditions can be a compound of general formula (1a), (1b), (1c), or a pharmaceutically acceptable salt or solvate thereof:
where
In certain embodiments a compound comprising the general formula (1a) is provided, wherein X1, X2, X3, X4 and X5 are independently from each other —C, —N, —S or —O wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently from each other —C or —N, m of R1m is 1, R1 is a substituted or unsubstituted C6 aryl or —(C═O)—R3, with R3 being a substituted or unsubstituted C6 heteroaryl, n of R2n is 1 or 2, each R2 independently from any other R2 is a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted C6 heteroaryl, a halogen, in some instances —F, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl.
In certain embodiments, a compound comprising the general formula (1b) is provided, wherein Z3, Z4 and Z5 are independently of each other —C, —N, —S or —O, A1, A2 and A3, are independently of each other —C, —N or —(C═O)—O—R7, with R7 being an alkyl, l of R5l is 1 or 2, each R5 is independently from each other a C1-C4 alkinyl or a halogen, in some instances —Cl, k of R6k is 1, 2, 3 or 4, in some instances 1 or 2, each R6 is independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen.
In certain embodiments, a compound comprising the general formula (1c) is provided, wherein Z1, Z2, Z3, Z4 and Z5 are independently of each other —C, —N, —S or —O, l of R5l is 1 or 2, each R5 is independently from each other a C1-C4 alkinyl or a halogen, in some instances —Cl, k of R6k is 1, 2, 3 or 4, in some instances 1 or 2, each R6 is independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen.
In certain embodiments, the compound comprises the general formula (1a), general formula (1b) or general formula (1c), wherein X1, X2, X3, X4 and X5 are independently from each other —C, —N, wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently from each other —C or —N, m of R1m is 1, R1 is a substituted or unsubstituted C6 aryl or —(C═O)—R3, with R3 being a substituted or unsubstituted C6 heteroaryl, n of R2n is 1 or 2, each R2 independently from any other R2 is a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted C6 heteroaryl, a halogen, in some instances —F, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, Z1, Z2, Z3, Z4 and Z5 are independently of each other —C, —N or —O, A1, A2 and A3, are independently of each other —C, —N or —(C═O)—O—R7, with R7 being an alkyl, l of R5l is 1 or 2, each R5 is independently from each other a C1-C4 alkinyl or a halogen, in some instances —Cl, k of R6k is 1, 2, 3 or 4, each R6 is independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen.
In certain embodiments a compound comprising the general formula (1a) is provided, wherein X1, X2, X3, X4 and X5 are independently from each other —C or —N, wherein at least two of X1, X2, X3, X4 and X5 are —N, Y1 and Y2 are independently from each other —C or —N, m of R1m, is 1, R1 is a substituted or unsubstituted C6 aryl or —(C═O)—R3, with R3 being a substituted or unsubstituted C6 heteroaryl, n of R2n is 1 or 2, each R2 independently from any other R2 is a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alcohol, a substituted or unsubstituted C6 heteroaryl, a halogen, in some instances —F, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl.
In certain embodiments, a compound comprising the general formula (1b) is provided, wherein Z3, Z4 and Z5 are independently of each other —C or —N, A1, A2 and A3, are independently of each other —C, —N or —(C═O)—O—R7, with R7 being an alkyl, l of R5l is 1 or 2, each R5 is independently from each other a C1-C4 alkinyl or a halogen, in some instances —Cl, k of R6k is 1, 2, 3 or 4, in some instances 1 or 2, each R6 is independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen.
In certain embodiments, a compound comprising the general formula (1c) is provided, wherein Z1, Z2, Z3, Z4 and Z5 are independently of each other —C, —N or —O, l of R5 is 1 or 2, each R5 is independently from each other a C1-C4 alkinyl or a halogen, in some instances —Cl, k of R6k is 1, 2, 3 or 4, in some instances 1 or 2, each R6 is independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl, oxygen or hydrogen.
A GABAA receptor modulator that can be used in the treatment of pain or associated conditions can be a compound of general formula (2), (3), (4), (5), (6) (7), or a pharmaceutically acceptable salt or solvate thereof,
with Y1, Y2, Z1, Z4, Z5, m of R1m, R1, R3, n of R2n, R2, R4, l of R5l, R5, k of R6k, R6, A1, A2 and A3 having the same meaning as defined above.
In some embodiments, the GABAA receptor modulator is a compound of formula (2), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (3), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (4), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (7), or a pharmaceutically acceptable salt or solvate thereof.
In certain embodiments, the compound comprises the general formula (2), (3), (4) or (5), with Y1, Y2, m of R1m, R3, n of R2n, R2 and R4 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (6) with Z1, Z4, Z5, l of R5l, R5, k of R6k and R6 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (7) with Z4, Z5, l of R5l, R5, k of R6k, R6, A1, A2 and A3 having the same meaning as defined above.
A GABAA receptor modulator that can be used in the treatment of pain or associated conditions can be a compound of general formula (2a), (3a), (4a), (5a), (5b), (6a), (6b), (7a), or a pharmaceutically acceptable salt or solvate thereof,
with m of R1m, R1, R3, n of R2n, R2, R4, l of R5l, R5, k of R6k and R6 having the same meaning as defined above.
In some embodiments, the GABAA receptor modulator is a compound of formula (2a), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (3a), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (4a), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5a), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5b), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6a), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6b), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (7a), or a pharmaceutically acceptable salt or solvate thereof.
In certain embodiments, the compound comprises the general formula (2a), (3a), (4a), (5a) or (5b) with m of R1m, R1, R3, n of R2n, R2 and R4 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (6a) or (6b) with m of l of R5l, R5, k of R6k and R6 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (7a) with m of l of R5l, R5, k of R6k and R6 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula 1a, 1b, 1c, 2, 3, 4, 5, 6, 7, 2a, 3a, 4a, 5a, 5b, 6a, 6b or 7a, wherein m of R1 is 1 and R1 is: an unsubstituted phenyl, a substituted phenyl comprising at least one —F as a substituent, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, or a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, or —(C═O)—R3, with R3 being pyridine, and l of R5 is 1 and R5 is Cl, Br, F, or a C2 alkinyl.
In certain embodiments, the compound comprises the general formula 1a, 2, 3, 4, 5, 2a, 3a, 4a, 5a or 5b, wherein m of R1 is 1 and R1 is: an unsubstituted phenyl, a substituted phenyl comprising at least one —F as a substituent, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, or a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, or —(C═O)—R3, with R3 being pyridine.
In certain embodiments, the compound comprises the general formula 1b, 7, or 7a, wherein l of R5 is 1 and R5 is Cl, Br, F, or a C2 alkinyl.
In certain embodiments, the compound comprises the general formula 1c, 6, 6a or 6b, wherein l of R5 is 1 and R5 is Cl, Br, F, or a C2 alkinyl.
In certain embodiments, the compound comprises the general formula 1a, 1b, 1c, 2, 3, 4, 5, 6, 7, 2a, 3a, 4a, 5s, 5b, 6a, 6b or 7a, wherein n of R2 is 1 or 2 and in case of n being 2, each R2 independently from each other is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances R4 being a substituted or unsubstituted triazole, an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, a halogen, in some instances —F, in case of n being 1, R2 is an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, an unsubstituted C6 heteroaryl, in some instances pyridine, and k of R6 is 1 or 4 and in case of k being 1, R6 is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, in case of k being 4, each R6 independently from each other is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, oxygen, or hydrogen.
In certain embodiments, the compound comprises the general formula 1a, 1b, 1c, 2, 3, 4, 5, 6, 7, 2a, 3a, 4a, 5a, 5b, 6a, 6b or 7a, wherein n of R2 is 1 or 2 and in case of n being 2, each R2 independently from each other is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances R4 being a substituted or unsubstituted triazole, an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, a halogen, in some instances —F, in case of n being 1, R2 is an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, an unsubstituted C6 heteroaryl, in some instances pyridine, and k of R6 is 1 or 4 and in case of k being 1, R6 is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, in case of k being 4, each R6 independently from each other is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, oxygen, or hydrogen.
In certain embodiments, the compound comprises the general formula 1a, 2, 3, 4, 5, 2a, 3a, 4a, 5a or 5b, wherein n of R2 is 1 or 2 and in case of n being 2, each R2 independently from each other is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances R4 being a substituted or unsubstituted triazole, an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, a halogen, in some instances —F, in case of n being 1, R2 is an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, an unsubstituted C6 heteroaryl, in some instances pyridine.
In certain embodiments, the compound comprises the general formula 1b, 7, or 7a, wherein k of R6 is 1 or 4 and in case of k being 1, R6 is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, in case of k being 4, each R6 independently from each other is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, oxygen, or hydrogen.
In certain embodiments, the compound comprises the general formula 1c, 6, 6a or 6b wherein k of R6 is 1 or 4 and in case of k being 1, R6 is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, in case of k being 4, each R6 independently from each other is a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, oxygen, or hydrogen.
In certain embodiments, the compound comprises the general formula 1a, 1b, 1c, 2, 3, 4, 5, 6, 7, 2a, 3a, 4a, 5s, 5b, 6a, 6b or 7a, wherein n of R2 is 2 and one R2 is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, or an unsubstituted C1-C6 alkyl, in some instances tert-butyl, and the other R2 is —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or one R2 is an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, and the other R2 is a halogen, in some instances —F, and k of R6 is 4 and two R6 are oxygen, the other R6 are independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen.
In certain embodiments, the compound comprises the general formula 1a, 2, 3, 4, 5, 2a, 3a, 4a, 5s or 5b, wherein n of R2 is 2 and one R2 is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, or an unsubstituted C1-C6 alkyl, in some instances tert-butyl, and the other R2 is O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or one R2 is an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, and the other R2 is a halogen, in some instances —F.
In certain embodiments, the compound comprises the general formula 1b, 7, or 7a, wherein k of R6 is 4 and two R6 are oxygen, the other R6 are independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen.
In certain embodiments, the compound comprises the general formula 1c, 6, 6a or 6b, wherein k of R6 is 4 and two R6 are oxygen, the other R6 are independently from each other a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C3 alkyl, or hydrogen.
A GABAA receptor modulator that can be used in the treatment of pain or an associated condition can be a compound of general formula (2a′), (3a′), (4a′), (5a′), (5b′), (6a′), (6b′), (7a′), or a pharmaceutically acceptable salt or solvate thereof,
with R1, R3 n of R2n, R2, R4, R5, k of R6k and R6 having the same meaning as defined above.
In some embodiments, the GABAA receptor modulator is a compound of formula (2a′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (3a′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (4a′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5a′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5b′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6a′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6b′), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (7a′), or a pharmaceutically acceptable salt or solvate thereof.
In certain embodiments, the compound comprises the general formula (2a′), (3a′), (4a′), (5a′) or (5b′) with R1, R3, n of R2n, R2 and R4 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (6a′) or (6b′) with k of R6k and R6 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (7a′) with k of R6k and R6 having the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (2a′), (3a′), (4a′), (5a′), (5b′), (6a′), (6b′) or (7a′), wherein R1 is in case of formula (2a′) a substituted or unsubstituted C6 aryl, in some instances an unsubstituted phenyl, a substituted phenyl comprising at least one —F as a substituent, in case of formula (3a′), (5a′) or (5b′), a substituted or unsubstituted biphenyl, in some instances an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, or in case of formula (4a′), —(C═O)—R3, with R3 being a substituted or unsubstituted C6 heteroaryl, in some instances with R3 being pyridine, R5 is in case of formula (6a′) or (6b′), Cl, Br or F, in case of formula (7a′) C2 alkinyl, wherein R2n and R6k have the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (2a′), (3a′), (4a′), (5a′) or (5b′) wherein R1 is in case of formula (2a′) a substituted or unsubstituted C6 aryl, in some instances an unsubstituted phenyl, a substituted phenyl comprising at least one —F as a substituent, in case of formula (3a′), (5a′) or (5b′), a substituted or unsubstituted biphenyl, in some instances an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, or in case of formula (4a′), —(C═O)—R3, with R3 being a substituted or unsubstituted C6 heteroaryl, in some instances with R3 being pyridine, wherein R2n has the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (6a′) or (6b′), wherein R5 is Cl, Br or F, wherein R6k has the same meaning as defined above.
In certain embodiments, the compound comprises the general formula (7a′), wherein R5 is C2 alkinyl, wherein R6k has the same meaning as defined above.
A GABAA receptor modulator that can be used in the treatment of pain or associated conditions can be a compound of general formula (2a″), (3a″), (4a″), (5a″), (5b″), (6a″), (7a″), or a pharmaceutically acceptable salt or solvate thereof,
with R7 being an unsubstituted C1-C6 alkyl, in some instances tert-butyl, an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in some instances R7 being in case of formula (2a″) an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, or R7 being in case of formula (5a″) or (5b″) an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, R8 being —O—CH 2-R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in some instances R8 being in case of formula (2a″) —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or R8 being in case of formula (3a″) an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, R9 being an unsubstituted C6 heteroaryl, in some instances pyridine, or a halogen, in some instances —F, R9 being in case of formula (4a″) an unsubstituted C6 heteroaryl, in some instances pyridine, or R9 being in case of formula (5b″) a halogen, in some instances —F, R10 being a C1-C3 alkyl or hydrogen, R11 being a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, in some instances R11 being in case of formula (6a″) an substituted or unsubstituted aryl, in some instances phenyl R11 being in case of formula (7a″) a substituted or unsubstituted heteroaryl, in some instances pyridine, a substituted or unsubstituted aryl, in some instances phenyl, R5 being in case of formula (6a″), Cl, Br or F, in case of formula (7a″) C2 alkinyl.
In some embodiments, the GABAA receptor modulator is a compound of formula (2a″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (3a″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (4a″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5a″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (5b″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (6a″), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the GABAA receptor modulator is a compound of formula (7a″), or a pharmaceutically acceptable salt or solvate thereof.
In certain embodiments, the compound comprises the general formula (2a″), (3a″), (4a″), (5a″) or (5b″) with R7 being an unsubstituted C1-C6 alkyl, in some instances tert-butyl, an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in some instances R7 being in case of formula (2a″) an unsubstituted C1-C6-alkyl, in some instances tert-butyl, or an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, or R7 being in case of formula (5a″) or (5b″) an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, R8 being —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in some instances R8 being in case of formula (2a″) —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, or R8 being in case of formula (3a″) an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, R9 being an unsubstituted C6 heteroaryl, in some instances pyridine, or a halogen, in some instances —F, R9 being in case of formula (4a″) an unsubstituted C6 heteroaryl, in some instances pyridine, or R9 being in case of formula (5b″) a halogen, in some instances —F.
In certain embodiments, the compound for treatment of pain or associated conditions comprises the general formula (6a″) with R10 being a C1-C3 alkyl or hydrogen, R11 being a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, in some instances R11 being in case of formula (6a″) an substituted or unsubstituted aryl, in some instances phenyl R11 being in case of formula (7a″) a substituted or unsubstituted heteroaryl, in some instances pyridine, R5 being Cl, Br or F.
In certain embodiments, the compound comprises the general formula (7a″) with R11 being a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, in some instances R11 being in case of formula (6a″) an substituted or unsubstituted aryl, in some instances phenyl R11 being in case of formula (7a″) a substituted or unsubstituted heteroaryl, in some instances pyridine, R5 being C2 alkinyl.
In certain embodiments, the compound comprises the general formula (2a″), (3a″), (4a″), (5a″) or (5b″) with in case of formula (2a″) R1 being or an unsubstituted phenyl, a substituted phenyl comprising at least one —F as a substituent, R7 being an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, and R8 being —O—CH2—R4, with R4 being a substituted or unsubstituted C4 heteroaryl, in some instances a substituted or unsubstituted triazole, in case of formula (3a″) R1 being an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, being an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in case of formula (4a″) R1 being —(C═O)—R3, with R3 being an unsubstituted C6 heteroaryl, in some instances R3 being pyridine, and R9 being an unsubstituted C6 heteroaryl, in some instances pyridine, in case of formula (5a″) R1 being an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, R7 being an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, in case of formula (5a″) R1 being an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, R7 being an unsubstituted C1-C6 alcohol, in some instances a C4 alcohol, R9 being a halogen, in some instances —F.
A GABAA receptor modulator that can be used in the treatment of pain or associated conditions can be a compound of general formula (8), or a pharmaceutically acceptable salt or solvate thereof,
where
In certain embodiments, the compound is selected from the compounds depicted in
According to a first subaspect of the invention, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and conditions associated with fibromyalgia. In some cases, a compound can be a compound of general formula (1a), general formula (1b), general formula (1c), or a pharmaceutically acceptable salt or solvate thereof,
in some instances formula (1a) and (1b), more particular
(1a), wherein
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (1a), general formula (1b) or general formula (1c), in some instances formula (1a) and (1b), more particular (1a), or a pharmaceutically acceptable salt or solvate thereof, wherein
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (2), (3), (4), (5), (1c) or (7), in some instances (2), (3), (4), (5) or (7), in some instances (2), (3), (4) or (5), or a pharmaceutically acceptable salt or solvate thereof,
with Y1, Y2, Z4, Z5, m or R1m, R1, R3, n of R2n, R2, R4, p of R12, q of R13, R13, l of R5l, R5, k of R6k, R6, A1, A2 and A3 having the same meaning as defined above.
In certain embodiments, the compound for treatment of fibromyalgia and associated conditions comprises the general formula (2a), (3a), (4a), (5a), (5b), (1c) or (7a), in some instances (2a) (3a), (4a) (5a), (5b) or (7a), in some instances (2a), (3a) (4a), (5a) or (5b), or a pharmaceutically acceptable salt or solvate thereof,
with m of R1m, R3, n of R2n, R2, R4, p of R12, R12, of R13, R13, l of R5l, R5, k of R6k and R6 having the same meaning as defined above.
In certain embodiments, m of R1 is 1 and R1 is: an unsubstituted phenyl, a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, —CN as substituents, wherein in some instances said substituted phenyl comprises at least one —F as a substituent, an unsubstituted biphenyl, a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, or a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one —F as a substituent, or —(C═O)—R3, with R3 being pyridine.
In certain embodiments, m of R1 is 1 and R1 is a substituted phenyl comprising C1-C4-alkyl, F, Cl, Br, I, —CN as substituents, wherein in some instances said substituted phenyl comprises at least one —F as a substituent. The substituted phenyl is a phenyl moiety according to formula (9),
wherein r is 1, 2, 3, 4 or 5 and R15 is F and s is 0, 1, 2, 3 or 4 and R16 is C1-C4-alkyl, Cl, Br, I, —CN, wherein the sum of r and s does not exceed 5.
In certain embodiments, m of R1 is 1 and R1 is a substituted phenyl according to formula (9), wherein r is 1 or 2 and R15 is F and wherein s is 0, 1, 2, 3 or 4 (in case of r being 2, s is 0, 1, 2 or 3) and R16 is C1-C4-alkyl, Cl, Br, I, —CN.
In certain embodiments, m of R1 is 1 and R1 is a substituted phenyl according to formula (9), wherein r is 1 or 2 and R15 is F and wherein s is 0.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety. The substituted biphenyl can be a biphenyl moiety according to formula (10),
wherein t is 0, 1, 2, 3 or 4, u is 0, 1, 2, 3, 4 or 5 and R17 is —CN, wherein at least t and/or u is equal or greater 1, v is 0, 1, 2, 3 or 4 and R18 is C1-C4-alkyl, Cl, Br, I or —CN, and w is 0, 1, 2, 3, 4 or 5 and R19 is C1-C4-alkyl, Cl, Br, I or —CN, wherein the sum of t, u, v and w does not exceed 9.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (10), wherein v and w are 0 or 1, R18 and R19 are C1-C4-alkyl, Cl, Br, I or —CN, t and/or u are 1 and R17 is —CN.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (10), wherein v and w are 0, t and/or u are 1 and R17 is —CN.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (10), wherein v, w and t are 0, u is 1 and R17 is —CN.
In certain embodiment, m of R1 is 1 and R1 is a substituted biphenyl comprising at least one —CN as a substituent, in some instances on the phenyl moiety not connected to the parent moiety, wherein in some instances one phenyl moiety comprises additionally at least one —F as a substituent, in some instances each phenyl moiety comprises additionally at least one substituent. This substituted biphenyl can be a biphenyl moiety according to formula (11),
wherein t is 0, 1, 2, 3 or 4, u is 0, 1, 2, 3, 4 or 5 and R17 is —CN, wherein at least t and/or u is equal or greater 1, v is 0, 1, 2, 3 or 4 and R18 is C1-C4-alkyl, Cl, Br, I or —CN, w is 0, 1, 2, 3, 4 or 5 and R19 is C1-C4-alkyl, Cl, Br, I or —CN, x is 0, 1, 2, 3, or 4, y is 0, 1, 2, 3, 4 or 5 and R20 is F, wherein at least x and/or y is equal or greater 1 wherein the sum of t, u, v, w, x and y does not exceed 9.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (11), wherein v and w are 0, t and/or u are 1, R17 is —CN, x and/or y are 1 and R20 is —F.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (11), wherein v, w and t are 0, u is 1, R17 is —CN, x and/or y are 1 and R20 is —F.
In certain embodiments, m of R1 is 1 and R1 is a substituted biphenyl according to formula (11), wherein v, w and t are 0, u is 1, R17 is —CN, x and y are 1 and R20 is —F.
in certain embodiments, n of R2 is 1 or 2 and R2 is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, an unsubstituted C1-C6 alkyl, in some instances tert-butyl, or —O—CH2—R4, with R4 being a substituted or unsubstituted 5-membered heteroaryl, in some instances R4 being a substituted or unsubstituted triazole, an unsubstituted C1-C6 alcohol, in some instances a C3 alcohol, in some instances isopropanol, a halogen, in some instances —F, an unsubstituted 6-membered heteroaryl, in some instances pyridine.
In certain embodiments, n of R2 is 2 and one R2 is an unsubstituted C3-C8 cycloalkyl, in some instances a C4-cycloalkyl, or an unsubstituted C1-C6 alkyl, in some instances tert-butyl, and the other R2 is O—CH2—R4, with R4 being a substituted or unsubstituted 5-membered heteroaryl, in some instances a substituted or unsubstituted triazole.
In certain embodiments, n of R2 is 2 and one R2 is an unsubstituted C1-C6 alcohol, in some instances a C3 alcohol, in some instances isopropanol, and the other R2 is a halogen, in some instances —F.
In certain embodiments, n of R2 is 1 and R2 is an unsubstituted C1-C6 alcohol or an unsubstituted 6-membered heteroaryl.
In certain embodiments, n of R2 is 1 and R2 is a C3 alcohol or pyridine.
In certain embodiments, n of R2 is 1 and R2 is a C3 alcohol.
In certain embodiments, n of R2 is 1 and R2 is isopropanol.
In certain embodiments, l of R5 is 1 and R5 is I, Cl, Br, F, or a C2 alkinyl.
In certain embodiments, l of R5 is 1 and R5 is I or a C2 alkinyl.
In certain embodiments, k of R6 is 1 and R6 is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted C1-C3 alkyl.
In certain embodiments, k of R6 is 1 and R6 is a substituted or unsubstituted C6 aryl, a 5- to 6-membered substituted or unsubstituted heteroaryl.
In certain embodiments, k of R6 is 1 and R6 is a phenyl, a phenyl substituted with F or Cl, thiophen or pyridine.
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI) or (7a′), in some instances (2a′), (3a′), (4a′), (5a′), (5b′) or (7a′), even in some instances (2a′), (3a′), (4a′), (5a′) or (5b′), or a pharmaceutically acceptable salt or solvate thereof,
wherein
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (2a′), (3a′), (4a′), (5a′), (5b′), (VI) or (7a′), in some instances (2a′), (3a′), (4a′), (5a′), (5b′) or (7a′), even in some instances (2a′), (3a′), (4a′), (5a′) or (5b′), or a pharmaceutically acceptable salt or solvate thereof, wherein
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (2a″), (3a″), (4a″), (5a″), (5b″), (Via″) or (7a″), in some instances (2a″), (3a″), (4a″), (5a″), (5b″) or (7a″), in some instances (2a″), (3a″), (4a″), (5a″) or (5b″), or a pharmaceutically acceptable salt or solvate thereof,
with R′ having the same meaning as defined above, and
In certain embodiments, a GABAA receptor modulator that can be used in the treatment of fibromyalgia and associated conditions can be a compound of general formula (2a″), (3a″), (4a″), (5a″), (5b″), or a pharmaceutically acceptable salt or solvate thereof,
with
In certain embodiments, the compound comprises the general formula (2a″), (3a″), (5a″) or (5b″), as described above.
In certain embodiment, the compound comprises the general formula (5a″), as described above.
A GABAA receptor modulator that can be used in the treatment of fibromyalgia or associated conditions can be a compound of general formula (8), or a pharmaceutically acceptable salt or solvate thereof,
where
In some cases, a GABAA receptor modulator that can be used in the treatment of pain and associated conditions can be a compound of formula (12), formula (13), formula (14), formula (15), formula (16), or formula (17), or a pharmaceutically acceptable salt or solvate thereof:
Also contemplated herein are deuterated forms of a compound described herein. A deuterated form of a compound can include a replacement of at least one hydrogen with at least one deuterium. In some cases, a deuterated compound for use in treating pain as described herein can be a compound of formula (17), or a pharmaceutically acceptable salt or solvate thereof.
In certain embodiments, the compound is selected from the compounds depicted in
In certain embodiments, a GABAA receptor modulator as described herein is Compound 1.
Also disclosed herein are pharmaceutical compositions comprising a GABAA receptor modulator as described herein. In some embodiments, a pharmaceutical composition can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more GABAA receptor modulators disclosed herein.
In some instances, a pharmaceutical composition can comprise a GABAA receptor modulator described herein and at least one of: an excipient, a diluent, or a carrier. In some cases, a GABAA receptor modulator described herein can be dissolved or suspended in a diluent or carrier.
In some embodiments, a pharmaceutical composition can comprise an excipient. An excipient can be an excipient described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986).
Non-limiting examples of suitable excipients can include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a chelator, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, a coloring agent.
In some embodiments an excipient can be a buffering agent. Non-limiting examples of suitable buffering agents can include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate. As a buffering agent, sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium glucomate, aluminum hydroxide, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide and other calcium salts or combinations thereof can be used in a pharmaceutical composition.
In some embodiments an excipient can comprise a preservative. Non-limiting examples of suitable preservatives can include antioxidants, such as alpha-tocopherol and ascorbate, and antimicrobials, such as parabens, chlorobutanol, and phenol. Antioxidants can further include but not limited to EDTA, citric acid, ascorbic acid, butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), sodium sulfite, p-amino benzoic acid, glutathione, propyl gallate, cysteine, methionine, ethanol and N-acetyl cysteine. In some instances a preservatives can include validamycin A, TL-3, sodium ortho vanadate, sodium fluoride, N-a-tosyl-Phe-chloromethylketone, N-a-tosyl-Lys-chloromethylketone, aprotinin, phenylmethylsulfonyl fluoride, diisopropylfluorophosphate, kinase inhibitor, phosphatase inhibitor, caspase inhibitor, granzyme inhibitor, cell adhesion inhibitor, cell division inhibitor, cell cycle inhibitor, lipid signaling inhibitor, protease inhibitor, reducing agent, alkylating agent, antimicrobial agent, oxidase inhibitor, or other inhibitor.
In some embodiments a pharmaceutical composition can comprise a binder as an excipient. Non-limiting examples of suitable binders can include starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, and combinations thereof.
The binders that can be used in a pharmaceutical composition can be selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatin; cellulose derivatives such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, ethyl cellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol and water or a combination thereof.
In some embodiments a pharmaceutical composition can comprise a lubricant as an excipient. Non-limiting examples of suitable lubricants can include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil. The lubricants that can be used in a pharmaceutical composition can be selected from metallic stearates (such as magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulfates (such as sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talc or a combination thereof.
In some embodiments a pharmaceutical composition can comprise a dispersion enhancer as an excipient. Non-limiting examples of suitable dispersants can include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.
In some embodiments a pharmaceutical composition can comprise a disintegrant as an excipient. In some embodiments a disintegrant can be a non-effervescent disintegrant. Non-limiting examples of suitable non-effervescent disintegrants can include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth. In some embodiments a disintegrant can be an effervescent disintegrant. Non-limiting examples of suitable effervescent disintegrants can include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
In some embodiments an excipient can comprise a flavoring agent. Flavoring agents incorporated into an outer layer can be chosen from synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; and combinations thereof. In some embodiments a flavoring agent can be selected from the group consisting of cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
In some embodiments an excipient can comprise a sweetener. Non-limiting examples of suitable sweeteners can include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as a sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like.
In some instances, a pharmaceutical composition can comprise a coloring agent. Non-limiting examples of suitable color agents can include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C). A coloring agent can be used as dyes or their corresponding lakes.
In some instances, a pharmaceutical composition can comprise a diluent. Non-limiting examples of diluents can include water, glycerol, methanol, ethanol, and other similar biocompatible diluents. In some cases, a diluent can be an aqueous acid such as acetic acid, citric acid, maleic acid, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or similar. In some instances, a diluent can be used to titrate a pH of a compound to a pH such as physiological pH to produce a salt as described above. In other cases, a diluent can be selected from a group comprising alkaline metal carbonates such as calcium carbonate; alkaline metal phosphates such as calcium phosphate; alkaline metal sulfates such as calcium sulfate; cellulose derivatives such as cellulose, microcrystalline cellulose, cellulose acetate; magnesium oxide, dextrin, fructose, dextrose, glyceryl palmitostearate, lactitol, caoline, lactose, maltose, mannitol, simethicone, sorbitol, starch, pregelatinized starch, talc, xylitol and/or anhydrates, hydrates and/or pharmaceutically acceptable derivatives thereof or combinations thereof.
In other embodiments, a pharmaceutical composition can comprise a surfactant. Surfactants can be selected from, but not limited to, polyoxyethylene sorbitan fatty acid esters (polysorbates), sodium lauryl sulfate, sodium stearyl fumarate, polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols (PEG), polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, amino acids such as L-leucine, sugar esters of fatty acids, glycerides of fatty acids or a combination thereof.
A pharmaceutical composition disclosed herein can be formulated into a variety of forms and administered by a number of different means. A pharmaceutical composition can be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired. The term “parenteral” as used herein can include subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. Administration can include injection or infusion, including intra-arterial, intracardiac, intracerebroventricular, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalational, transdermal, transmucosal, sublingual, buccal and topical (including epicutaneous, dermal, enema, eye drops, ear drops, intranasal, vaginal) administration. In some exemplary embodiments, a route of administration can be via an injection such as an intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
Solid dosage forms for oral administration can include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules. A capsule can comprise a core material comprising a nutritive protein or composition and a shell wall that encapsulates a core material. In some embodiments a core material can comprise at least one of a solid, a liquid, and an emulsion. In some embodiments a shell wall material can comprise at least one of a soft gelatin, a hard gelatin, and a polymer. Suitable polymers can include but not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, such as those formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name “Eudragit”); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers; and shellac (purified lac). In some embodiments at least one polymer can function as taste-masking agents.
Tablets, pills, and the like can be compressed, multiply compressed, multiply layered, and/or coated. A coating can be single or multiple. In some embodiments, a coating material can comprise at least one of a saccharide, a polysaccharide, and glycoproteins extracted from at least one of a plant, a fungus, and a microbe. Non-limiting examples can include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum. In some embodiments a coating material can comprise a protein. In some embodiments, a coating material can comprise at least one of a fat and/or an oil. In some embodiments the at least one of a fat and/or an oil can be high temperature melting. In some embodiments the at least one of a fat and/or an oil can be hydrogenated or partially hydrogenated. In some embodiments the at least one of a fat and/or an oil can be derived from a plant. In some embodiments the at least one of a fat and/or an oil can comprise at least one of glycerides, free fatty acids, and fatty acid esters. In some embodiments a coating material can comprise at least one edible wax. An edible wax can be derived from animals, insects, or plants. Non-limiting examples can include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills can additionally be prepared with enteric coatings.
Liquid formulations can include a syrup (for example, an oral formulation), an intravenous formulation, an intranasal formulation, an ocular formulation (e.g. for treating an eye infection), an otic formulation (e.g. for treating an ear infection), an ointment, a cream, an aerosol, and the like. In some instances, a combination of various formulations can be administered. In some embodiments, a tablet, pill, and the like can be formulated for an extended release profile.
Dosing and Administration
In some cases, a GABAA receptor modulator, salt thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt thereof described herein can be administered at a dose of from about 1 mg to about 1000 mg, from about 5 mg to about 1000 mg, from about 10 mg to about 1000 mg, from about 15 mg to about 1000 mg, from about 20 mg to about 1000 mg, from about 25 mg to about 1000 mg, from about 30 mg to about 1000 mg, from about 35 mg to about 1000 mg, from about 40 mg to about 1000 mg, from about 45 mg to about 1000 mg, from about 50 mg to about 1000 mg, from about 55 mg to about 1000 mg, from about 60 mg to about 1000 mg, from about 65 mg to about 1000 mg, from about 70 mg to about 1000 mg, from about 75 mg to about 1000 mg, from about 80 mg to about 1000 mg, from about 85 mg to about 1000 mg, from about 90 mg to about 1000 mg, from about 95 mg to about 1000 mg, from about 100 mg to about 1000 mg, from about 150 mg to about 1000 mg, from about 200 mg to about 1000 mg, from about 250 mg to about 1000 mg, from about 300 mg to about 1000 mg, from about 350 mg to about 1000 mg, from about 400 mg to about 1000 mg, from about 450 mg to about 1000 mg, from about 500 mg to about 1000 mg, from about 550 mg to about 1000 mg, from about 600 mg to about 1000 mg, from about 650 mg to about 1000 mg, from about 700 mg to about 1000 mg, from about 750 mg to about 1000 mg, from about 800 mg to about 1000 mg, from about 850 mg to about 1000 mg, from about 900 mg to about 1000 mg, or from about 950 mg to about 1000 mg.
In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt thereof described herein can be administered at a dose of about 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179 180, 181, 182, 183, 184, 184, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 mg.
In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt thereof described herein can be administered at a dose with respect to a subject body weight. In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt or solvate thereof described herein can be administered at a dose of from about 0.05 mg/kg to about 100 mg/kg, from about 0.005 mg/kg to about 95 mg/kg, from about 0.005 mg/kg to about 90 mg/kg, from about 0.005 mg/kg to about 85 mg/kg, from about 0.005 mg/kg to about 80 mg/kg, from about 0.005 mg/kg to about 75 mg/kg, from about 0.005 mg/kg to about 70 mg/kg, from about 0.005 mg/kg to about 65 mg/kg, from about 0.005 mg/kg to about 60 mg/kg, from about 0.005 mg/kg to about 55 mg/kg, from about 0.005 mg/kg to about 50 mg/kg, from about 0.005 mg/kg to about 45 mg/kg, from about 0.005 mg/kg to about 40 mg/kg, from about 0.005 mg/kg to about 35 mg/kg, from about 0.005 mg/kg to about 30 mg/kg, from about 0.005 mg/kg to about 25 mg/kg, from about 0.005 mg/kg to about 20 mg/kg, from about 0.005 mg/kg to about 15 mg/kg, or from about 0.005 mg/kg to about 10 mg/kg, with respect to a body weight of a subject. In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt or solvate thereof described herein can be administered at a dose of from about 0.2 mg/kg to about 10 mg/kg, from about 0.2 mg/kg to about 9 mg/kg, from about 0.2 mg/kg to about 8 mg/kg, from about 0.2 mg/kg to about 7 mg/kg, from about 0.2 mg/kg to about 6 mg/kg, from about 0.2 mg/kg to about 5 mg/kg, from about 0.2 mg/kg to about 4 mg/kg, from about 0.2 mg/kg to about 3 mg/kg, from about 0.2 mg/kg to about 2 mg/kg, or from about 0.2 mg/kg to about 1 mg/kg, with respect to a body weight of a subject. In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt or solvate thereof described herein can be administered at a dose of from about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg, or about 0.005 mg/kg to about 0.01 mg/kg, about 0.02 mg/kg, about 0.03 mg/kg, about 0.04 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, or about 1 mg/kg, with respect to a body weight of a subject.
In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt thereof described herein can be administered at a dose of less than about 0.001 mg/kg, less than 0.002 mg/kg, less than 0.003 mg/kg, less than 0.004 mg/kg, less than 0.005 mg/kg, less than 0.006 mg/kg, less than 0.007 mg/kg, less than 0.008 mg/kg, less than 0.009 mg/kg, less than 0.01 mg/kg, less than 0.02 mg/kg, less than 0.03 mg/kg, less than 0.04 mg/kg, less than 0.05 mg/kg, less than 0.06 mg/kg, less than 0.07 mg/kg, less than 0.08 mg/kg, less than 0.09 mg/kg, less than 0.1 mg/kg, less than 0.2 mg/kg, less than 0.3 mg/kg, less than 0.4 mg/kg, less than 0.5 mg/kg, less than 0.6 mg/kg, less than 0.7 mg/kg, less than 0.8 mg/kg, less than 0.9 mg/kg, less than 1 mg/kg, less than 1.1 mg/kg, less than 1.2 mg/kg, less than 1.3 mg/kg, less than 1.4 mg/kg, less than 1.5 mg/kg, less than 1.6 mg/kg, less than 1.7 mg/kg, less than 1.8 mg/kg, less than 1.9 mg/kg, less than 2 mg/kg, less than 2.1 mg/kg, less than 2.2 mg/kg, less than 2.3 mg/kg, less than 2.4 mg/kg, less than 2.5 mg/kg, less than 2.6 mg/kg, less than 2.7 mg/kg, less than 2.8 mg/kg, less than 2.9 mg/kg, less than 3 mg/kg, less than 3.1 mg/kg, less than 3.2 mg/kg, less than 3.3 mg/kg, less than 3.4 mg/kg, less than 3.5 mg/kg, less than 3.6 mg/kg, less than 3.7 mg/kg, less than 3.8 mg/kg, less than 3.9 mg/kg, less than 4 mg/kg, less than 4.1 mg/kg, less than 4.2 mg/kg, less than 4.3 mg/kg, less than 4.4 mg/kg, less than 4.5 mg/kg, less than 4.6 mg/kg, less than 4.7 mg/kg, less than 4.8 mg/kg, less than 4.9 mg/kg, less than 5 mg/kg, less than 5.1 mg/kg, less than 5.2 mg/kg, less than 5.3 mg/kg, less than 5.4 mg/kg, less than 5.5 mg/kg, less than 5.6 mg/kg, less than 5.7 mg/kg, less than 5.8 mg/kg, less than 5.9 mg/kg, less than 6 mg/kg, less than 6.1 mg/kg, less than 6.2 mg/kg, less than 6.3 mg/kg, less than 6.4 mg/kg, less than 6.5 mg/kg, less than 6.6 mg/kg, less than 6.7 mg/kg, less than 6.8 mg/kg, less than 6.9 mg/kg, less than 7 mg/kg, less than 7.1 mg/kg, less than 7.2 mg/kg, less than 7.3 mg/kg, less than 7.4 mg/kg, less than 7.5 mg/kg, less than 7.6 mg/kg, less than 7.7 mg/kg, less than 7.8 mg/kg, less than 7.9 mg/kg, less than 8 mg/kg, less than 8.1 mg/kg, less than 8.2 mg/kg, less than 8.3 mg/kg, less than 8.4 mg/kg, less than 8.5 mg/kg, less than 8.6 mg/kg, less than 8.7 mg/kg, less than 8.8 mg/kg, less than 8.9 mg/kg, less than 9 mg/kg, less than 9.1 mg/kg, less than 9.2 mg/kg, less than 9.3 mg/kg, less than 9.4 mg/kg, less than 9.5 mg/kg, less than 9.6 mg/kg, less than 9.7 mg/kg, less than 9.8 mg/kg, less than 9.9 mg/kg, less than 10 mg/kg, less than 11 mg/kg, less than 12 mg/kg, less than 13 mg/kg, less than 14 mg/kg, less than 15 mg/kg, less than 16 mg/kg, less than 17 mg/kg, less than 18 mg/kg, less than 19 mg/kg, less than 20 mg/kg, less than 21 mg/kg, less than 22 mg/kg, less than 23 mg/kg, less than 24 mg/kg, less than 25 mg/kg, less than 26 mg/kg, less than 27 mg/kg, less than 28 mg/kg, less than 29 mg/kg, less than 30 mg/kg, less than 31 mg/kg, less than 32 mg/kg, less than 33 mg/kg, less than 34 mg/kg, less than 35 mg/kg, less than 36 mg/kg, less than 37 mg/kg, less than 38 mg/kg, less than 39 mg/kg, less than 40 mg/kg, less than 41 mg/kg, less than 42 mg/kg, less than 43 mg/kg, less than 44 mg/kg, less than 45 mg/kg, less than 46 mg/kg, less than 47 mg/kg, less than 48 mg/kg, less than 49 mg/kg, or less than 50 mg/kg. In some cases, a GABAA receptor modulator, salt or solvate thereof, or pharmaceutical composition comprising a GABAA receptor modulator or salt thereof described herein can be administered at a dose of at most about 0.001 mg/kg, at most about 0.002 mg/kg, at most about 0.003 mg/kg, at most about 0.004 mg/kg, at most about 0.005 mg/kg, at most about 0.006 mg/kg, at most about 0.007 mg/kg, at most about 0.008 mg/kg, at most about 0.009 mg/kg, at most about 0.01 mg/kg, at most about 0.02 mg/kg, at most about 0.03 mg/kg, at most about 0.04 mg/kg, at most about 0.05 mg/kg, at most about 0.06 mg/kg, at most about 0.07 mg/kg, at most about 0.08 mg/kg, at most about 0.09 mg/kg, at most about 0.1 mg/kg, at most about 0.2 mg/kg, at most about 0.3 mg/kg, at most about 0.4 mg/kg, at most about 0.5 mg/kg, at most about 0.6 mg/kg, at most about 0.7 mg/kg, at most about 0.8 mg/kg, at most about 0.9 mg/kg, at most about 1 mg/kg, at most about 1.5 mg/kg, at most about 2.0 mg/kg or at most about 3.0 mg/kg.
Administration of a GABAA receptor modulator, salt or solvate thereof, or composition can be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times a day. In some cases, administration of a GABAA receptor modulator, salt or solvate thereof, or composition can be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a week. In some cases, administration of a GABAA receptor modulator, salt or solvate thereof, or composition can be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 times a month.
The invention is further illustrated by the following examples, from which further embodiments and advantages can be drawn. These examples are meant to illustrate the invention but not to limit its scope.
An exemplary GABAA receptor modulator was formulated prior to administration. The exemplary GABAA receptor modulator was provided as a yellow powder at a purity of 98.87%. The dry solid was dissolved in 0.5% methyl cellulose in water. Various concentrations of the exemplary GABAA receptor modulator were prepared. For example, a 0.6 mg/mL test article was prepared by dissolving 10.9 mg of the phosphate salt of the exemplary GABAA receptor modulator in 14.5 mL of the 0.5% methyl cellulose.
Control solutions of 0.5% methyl cellulose and pregabalin in phosphate buffered saline (PBS) were prepared and set aside for comparison.
The purpose of the study is to assess the efficacy of the described compounds in the rat model of fibromyalgia pain.
Inclusion Criteria:
After the pre-treatment baseline assessment on Day 0, only animals that exhibit at least a 20% decrease in thresholds from pre-injury baseline to pre-dosing baseline were included in the study.
Blinding:
All testing was performed in a blinded manner, with all experimenters involved in the study being unaware of the group assignment of any animal they were testing. One staff member prepared the dose formulations, coded the syringes of solutions (e.g. 1-5), and created the blind (treatment key).
Group Assignment:
Animals were assigned to treatment groups based on Day 0 pre-dose von Frey 50% response thresholds so that group means of the mean paw withdrawal latencies were approximately equal. Animals were ranked by pre- and post-reserpine baseline change from lowest to highest, and treatments were assigned randomly within stratified sub-groups according to the total number of treatment groups in the study.
Dosing:
The volume of compound 1 or control article injected was 5 mL/kg. The animals were dosed in sequence based on animal number, so that the distribution of treatment across a given set of animals was not predictable.
Animal Model
Rats were the model of choice for the study of pain due to many similarities of the peripheral and central nervous systems of rats and humans. These similarities are evident both in terms of behavioral responses to painful conditions and in terms of pain relieving effects of various therapeutic agents (i.e. opioids, nonsteroidal anti-inflammatory drugs, anticonvulsants and antidepressants) in both species. Rats are among the best species for determining the predictability of efficacy of therapeutic agents in humans. Further, given the primary goal of these studies is to investigate the pain causing effects of compounds, it is necessary to use vertebrate animals when using whole animal models.
A total of 54 rats were requested for this study to ensure that enough animals were prepared that meet study criteria (n=10 per group, 4 groups). 14 more animals were requested for reserpine treatment as a success rate of ˜70% was expected, i.e., ˜30% of the rats treated with reserpine either are euthanized early for weight loss or do not meet the study inclusion criteria for mechanical sensitivity. Therefore, to ensure 10 rats per study group (n=40), 54 animals were treated with reserpine.
The appropriate group size (n=10) was selected to detect a response difference of 2.5 units with a power of 80% (standard deviation=3). The number of animals requested was consistent with the sample group sizes reported in peer reviewed research articles and in previous studies. Previous experience with the model indicates that a group size of at least 10 animals per group was required to generate interpretable and reproducible results.
50% Response Threshold (g)
Mechanical fibromyalgia-associated allodynia is measured using 8 Semmes-Weinstein filaments (Stoelting©; Wood Dale, Ill., USA) with varying stiffness (0.04, 0.07, 0.16, 0.4, 1.0, 4.0, and 8.0 g) according to the up-down method 1. Animals were placed in individual acrylic chambers on a metal mesh surface and allowed to acclimate to their surroundings for a minimum of 15 minutes before testing. Each filament was presented perpendicular to the plantar surface with sufficient force to cause slight buckling against the paw and held for approximately 4 seconds or until a positive response is noted (paw sharply withdrawn). Testing was initiated with the 0.4 g filament. In the absence of a paw withdrawal response, the next stronger stimulus was presented. In the event of paw withdrawal, the next weaker stimulus was used. This process was repeated until 4 responses after the initial change in response (no response to positive response or positive response to no response) were obtained. If the animal does not respond after reaching the strongest filament or if the animal responded after reaching the weakest filament, the testing is stopped for that time point. The 50% response threshold is calculated using the formula:
50% response threshold (g)=(10(Xf+kδ))/10,000
Xf=value (in log units) of the final von Frey filament used
k=tabular value for the pattern of positive/negative responses (Chaplan et al. 1994, appendix 1, page 62)
δ=mean difference (in log units) between stimuli
The mean and standard error of the mean (SEM) is determined for each paw for each treatment group at each time point.
Experimental Timeline
Dosing Regimen
Statistical Analysis
To verify the development of mechanical fibromyalgia-associated allodynia due to reserpine treatment, median ipsilateral and contralateral paw response thresholds from the vehicle group were assessed prior to dosing and at post-dosing baseline. Mean response thresholds were compared using a Wilcoxon matched-pairs signed-rank test. Pre-dose baseline tests were significantly lower (
Four days after reserpine injections (study day 0), mechanical fibromyalgia-associated allodynia was assessed at baseline (prior to dosing) and 1, 2, and 4 hours post-dosing with either vehicle or the test article, an exemplary GABAA receptor modulator.
Four days after reserpine injections (study day 0), mechanical fibromyalgia-associated allodynia was assessed at baseline (prior to dosing) and approximately 1, 2, and 4 hours after administration of vehicle, compound 1, or pregabalin.
Methods were carried out as described as in Examples 2-4. The mean paw response thresholds for each treatment regimen are depicted in Table 4 below:
Discussion
Pain was induced by three daily doses of 1 mg/kg reserpine, and mechanical fibromyalgia-associated allodynia was assessed using von Frey filaments. Mechanical fibromyalgia-associated allodynia was measured prior to and the first reserpine injection and 4 days following the third injection. GABAA receptor modulators (0.3 or 3 mg/kg), pregabalin (30 mg/kg) or vehicle (0.5% methylcellulose) were administered 4 days after the last reserpine injection, with mechanical fibromyalgia-associated allodynia being assessed prior to, and at 1, 2, and 4 hours post-administration to determine the efficacy of GABAA receptor modulators in this model.
The objective of this study was to assess the efficacy of GABAA positive allosteric receptor modulators at two doses against fibromyalgia pain in a rat model. 40 animals in this study met the inclusion criteria after pre-dose baseline testing, operationally defined as at least a 20% decrease in thresholds from pre-injury baseline to pre-dosing baseline. Mechanical fibromyalgia-associated allodynia persisted in vehicle-treated animals throughout the pharmacological assessment period (1, 2, and 4 hours post-dosing).
Administration of the positive control, pregabalin (30 mg/kg, PO), significantly reversed mechanical fibromyalgia-associated allodynia at the 1, 2, and 4 hour time points.
There was significant reduction in mechanical fibromyalgia-associated allodynia observed at 1, 2, and 4 hours post-dosing orally for both GABAA receptor modulator concentrations (0.3 or 3 mg/kg). The efficacy of the two doses were generally similar at all time points, and did not appear to be waning at either dose level at the final (4 hour) time point. Accordingly, it is understandable that multiple dosages are tolerated and effective across a wide range. As such, additional dosages are described above in the section titled Dosing and Administration.
In summary, this study is valid with significant fibromyalgia-associated allodynia induced during the model creation process that was reversible by the administration of the positive control, pregabalin (30 mg/kg. P0). Administration of GABAA receptor modulators at both 0.3 mg/kg and 3 mg/kg significantly reversed the fibromyalgia-associated allodynia seen in this model using the dosing regimen and time points tested in this study.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application claims benefit of U.S. Provisional Patent Application No. 62/819,794 filed on Mar. 18, 2019, which is incorporated herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US20/23355 | 3/18/2020 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62819794 | Mar 2019 | US |
